---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-025869"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:23:15.997905+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cortexyme cuts workforce 53%, CEO/CSO depart amid clinical hold; pipeline pivots to COR588 and oncology

## Summary
- CEO Casey Lynch and CSO Stephen Dominy resigned Jan 28; COO/CFO Christopher Lowe appointed Interim CEO and director.
- Workforce reduced ~53% with expected annualized savings of $8.3M in 2022 and one-time costs of $1.9-$2.1M.
- Preliminary cash, cash equivalents & investments of $126.7M as of Dec 31, 2021 (unaudited).
- Pipeline: COR588 Phase 1 data expected Q2 2022; atuzaginstat IND for oral squamous cell carcinoma in Q1 2022; COR803 in IND-enabling studies.
- Atuzaginstat IND on clinical hold for Alzheimer's; company plans Phase 2 for COR588 after FDA interactions.

## SEC filing metadata
- accession: 0001193125-22-025869
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/d274026d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-025869
- JSON: https://secwatch.observer/filing/0001193125-22-025869.json
- Plain text: https://secwatch.observer/filing/0001193125-22-025869.txt

## Key facts
- Executive change
  Casey C. Lynch resigned as Chairperson of the Board at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chairperson of the Board
  source text: Ms. Lynch and Dr. Dominy tendered their resignation from the Board, effective as of January 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm
- Executive change
  Stephen S. Dominy resigned as Chief Scientific Officer and a member of the Board at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer and a member of the Board
  source text: On February 1, 2022, the Company announced the departure of Casey C. Lynch, the Company’s President, Chief Executive Officer and Chairperson of the Board, and Stephen S. Dominy, M.D., the Company’s Chief Scientific Officer and a member of the Board, effective as of January 28, 2022 (the “Departure Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm
- Executive change
  Casey C. Lynch resigned as President, Chief Executive Officer and Chairperson of the Board at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: President, Chief Executive Officer and Chairperson of the Board
  source text: On February 1, 2022, the Company announced the departure of Casey C. Lynch, the Company’s President, Chief Executive Officer and Chairperson of the Board, and Stephen S. Dominy, M.D., the Company’s Chief Scientific Officer and a member of the Board, effective as of January 28, 2022 (the “Departure Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm
- Executive change
  Christopher Lowe was appointed as Class III Director at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On February 2, 2022, the Board appointed Mr. Lowe to serve on the Board as a Class III Director, to fill the vacancy resulting from Ms. Lynch’s resignation from the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm
- Executive change
  Stephen S. Dominy resigned as Director at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Ms. Lynch and Dr. Dominy tendered their resignation from the Board, effective as of January 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm
- Executive change
  Christopher Lowe was appointed as Interim Chief Executive Officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: On January 28, 2022, the Company appointed Christopher Lowe, the Company’s Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”), to serve as the Interim Chief Executive Officer (“Interim CEO”) of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522025869/0001193125-22-025869-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.